Adial Pharmaceuticals, Inc. (ADIL) · Oct 16, 2026 · Other events

Adial annual meeting adjourned again as Nasdaq approval drags

Meeting adjourned — Nasdaq approval still pending

Adial’s annual meeting was adjourned again because Nasdaq has not approved its listing application, delaying key shareholder votes.

Adial is a clinical-stage biotechnology company developing therapies for addiction and related disorders, while also navigating Nasdaq listing and capital-market constraints. The company still cannot complete several shareholder votes. After reconvening on October 15, 2026, Adial again adjourned Proposals 3, 4, 5 and 6 because Nasdaq had not approved its Initial Listing Application. 〔0〕

This extends an already-known delay rather than creating a new strategic development. The meeting had already been postponed from September 17 to October 1 and then to October 15; the latest filing confirms that the Nasdaq-dependent corporate actions remain unresolved. The polls remain open, and shareholders who already voted do not need to act again unless they want to change their vote. 〔1〕

The business impact is mainly execution risk and timing. Until Nasdaq approval arrives, Adial cannot finish the votes tied to the listing application, leaving a key financing or capitalization-related step in limbo. The filing does not disclose a rejection, a new deadline, or any change to the proposals, so it signals delay and uncertainty rather than a definitive failure.

Bottom line: This is a modest negative because Nasdaq approval remains unresolved and the shareholder process is slipping again. It matters mainly as a further delay to Adial’s capital-markets and corporate-restructuring plans, not as a change to its drug-development story.

What to watch next

Further reconvened meeting after Nasdaq approval

Original filing on SEC EDGAR

More Adial Pharmaceuticals, Inc. news

Adial annual meeting adjourned again as Nasdaq approval drags | ADIL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.